What is Imaxio?
Founded in 2000 as a spin-off from the Medical Research Council and the University of Cambridge, Imaxio operates at the intersection of academic research and commercial pharmaceutical development. The company is primarily recognized for its IMX313 technology platform, an antigen re-engineering solution designed to enhance immunogenicity in poorly responsive antigens. By maintaining a diverse portfolio that includes a marketed vaccine for human leptospirosis alongside a pipeline of clinical and preclinical candidates, Imaxio occupies a unique niche in the global biotech landscape. The firm's operational model focuses on advancing projects through Phase I and Phase II clinical trials before pursuing out-licensing agreements with larger biopharmaceutical entities for Phase III development and commercialization.
How much funding has Imaxio raised?
Imaxio has raised a total of $11.9M across 3 funding rounds:
Unspecified
$4M
Grant
$7.2M
Grant
$772K
Unspecified (2012): $4M, investors not publicly disclosed
Grant (2013): $7.2M led by Jenner Institute
Grant (2014): $772K supported by Agence nationale de la recherche ANR
Key Investors in Imaxio
Jenner Institute
A leading non-profit research organization based at the University of Oxford, specializing in the rapid early-stage development and clinical assessment of innovative vaccines for global infectious diseases.
Agence nationale de la recherche ANR
The French national funding agency that supports project-based research across diverse scientific disciplines, facilitating innovation in public health and sustainable development.
Undisclosed Investor
An undisclosed investor participating in the early-stage financing round to support the foundational growth of the company's biotech pipeline.
What's next for Imaxio?
With the recent influx of capital, Imaxio is well-positioned to accelerate its R&D pipeline and strengthen its competitive standing in the immunology sector. The strategic focus remains on the maturation of its clinical-stage projects, leveraging the IMX313 platform to address unmet medical needs. As the company continues to refine its antigen re-engineering capabilities, it remains actively engaged in seeking new collaborations with partners interested in high-efficacy vaccine development. The current funding context suggests a transition toward more intensive clinical validation phases, which will likely serve as the primary catalyst for future value creation and potential licensing opportunities with global pharmaceutical leaders.
See full Imaxio company page
